Join Growin Stock Community!

Summit therapeutics inc.SMMT.US Overview

US StockHealthcare
(No presentation for SMMT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SMMT AI Insights

SMMT Overall Performance

SMMT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SMMT Recent Performance

-2.32%

Summit therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

SMMT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SMMT Key Information

SMMT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SMMT Profile

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Price of SMMT

SMMT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SMMT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
753.90
PB Ratio
61.18
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
753.90
PB Ratio
61.18
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SMMT's latest earnings report released?

    The most recent financial report for Summit therapeutics inc. (SMMT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SMMT's short-term business performance and financial health. For the latest updates on SMMT's earnings releases, visit this page regularly.

  • How much debt does SMMT have?

    As of the end of the reporting period, Summit therapeutics inc. (SMMT) had total debt of 20.89M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SMMT have?

    At the end of the period, Summit therapeutics inc. (SMMT) held Total Cash and Cash Equivalents of 225.58M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SMMT's EPS continuing to grow?

    According to the past four quarterly reports, Summit therapeutics inc. (SMMT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SMMT?

    Summit therapeutics inc. (SMMT)'s Free Cash Flow (FCF) for the period is -102.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 109.71% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SMMT?

    The latest valuation data shows Summit therapeutics inc. (SMMT) has a Price-To-Earnings (PE) ratio of -11.56 and a Price/Earnings-To-Growth (PEG) ratio of 1.54. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.